Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.

@article{Liu2016IrinotecanDB,
  title={Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.},
  author={X. Liu and A. Situ and Yanan Kang and K. R. Villabroza and Y. Liao and C. Chang and T. Donahue and A. Nel and Huan Meng},
  journal={ACS nano},
  year={2016},
  volume={10 2},
  pages={
          2702-15
        }
}
Urgent intervention is required to improve the 5 year survival rate of pancreatic ductal adenocarcinoma (PDAC). While the four-drug regimen, FOLFIRINOX (comprising irinotecan, 5-fluorouracil, oxaliplatin, and leucovorin), has a better survival outcome than the more frequently used gemcitabine, the former treatment platform is highly toxic and restricted for use in patients with good performance status. Since irinotecan contributes significantly to FOLFIRINOX toxicity (bone marrow and… Expand
ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer
TLDR
A novel ADAM9-responsive, protease-dependent, drug delivery system for PDAC as a promising tool to reduce the cytotoxicity of systemic chemotherapy is introduced. Expand
Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer.
TLDR
Improved drug delivery was accompanied by substantially improved efficacy, increased survival, and reduced bone marrow and GI toxicity compared to the free drug and Onivyde, and the Ir-silicasome appears to be promising as a treatment option for CRC in humans based on improved efficacy and the carrier's favorable safety profile. Expand
Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer
TLDR
It is demonstrated that iRGD enhances the efficacy of irinotecan-loaded silicasome–based therapy and may be a suitable adjuvant in nanoparticle-based treatments for PDAC. Expand
Dacarbazine-Loaded Hollow Mesoporous Silica Nanoparticles Grafted with Folic Acid for Enhancing Antimetastatic Melanoma Response.
TLDR
In vivo investigations demonstrate that the rationally designed nanocarrier loaded with DTIC achieves significant improvement against lung metastasis of melanoma via targeting melanoma cells and tumor-associated macrophages. Expand
Targeted drug delivery using iRGD peptide for solid cancer treatment.
TLDR
This focused review summarized the design and implementation strategy for iRGD-mediated tumor targeting, including the working principle of such peptide and discussion on patient-specific iR GD effect in vivo, commensurate with the level of key biomarker expression on tumor vasculature. Expand
Irinotecan delivery by unimolecular micelles composed of reduction-responsive star-like polymeric prodrug with high drug loading for enhanced cancer therapy.
TLDR
It is demonstrated that CPIO carrier could provide a rational design of a stimuli-responsive polymeric prodrug for delivery of irinotecan and showed excellent biocompatibility in vivo after intravenous injection on a mouse model. Expand
Enhanced Efficacy and Drug Delivery with Lipid Coated Mesoporous Silica Nanoparticles in Cancer Therapy.
  • Muhammad Umair Amin, Sajid Ali, +6 authors J. Brüßler
  • Medicine
  • European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
  • 2021
TLDR
The Lip-Dox-MSNPs are proposed as an effective approach to treat cancer by delivering and maintaining effective concentration of drugs to the tumor site without systemic side effects. Expand
Engineered borate ester conjugated protein-polymer nanoconjugates for pH-responsive drug delivery.
  • P. Zhou, Shuang Wu, +4 authors Xin Huang
  • Materials Science, Medicine
  • Materials science & engineering. C, Materials for biological applications
  • 2019
TLDR
A new DOX-conjugated protein polymer nanoconjugates (PPNCs) prodrugs delivery system was developed to improve the clinical efficiency of cytotoxic anticancer drugs and contribute a potential delivery strategy for cancer therapy. Expand
Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment
TLDR
A ratiometrically designed mesoporous silica nanoformulation with synergistic efficacy in subcutaneous and orthotopic PDAC mouse models is demonstrated and the performance of co-delivery nanoparticles is improved, leading to a long-lasting anti-PDAC effect in vivo. Expand
Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
TLDR
Nanocarriers that improve drug delivery efficiency and engage the host immune system against the tumor resulting in reduction of tumor growth and metastasis are developed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 79 REFERENCES
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
TLDR
This study shows that intraliposomal stabilization of CPT-11 using a polymeric or highly charged, nonpolymeric polyanionic trapping agent results in a markedly active antitumor agent with low toxicity. Expand
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
TLDR
PEP02 demonstrates moderate antitumour activity with a manageable side effect profile for metastatic, gemcitabine-refractory pancreatic cancer patients, and a phase 3 trial of PEP02 (MM-398), known as NAPOLI-1, is currently underway. Expand
Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.
TLDR
Proof-of-principle testing of the use of a dual drug/siRNA nanocarrier to overcome Dox resistance in a xenograft is provided and the first detailed analysis of the impact of heterogeneity in the tumor microenvironment on the efficacy of siRNA delivery in vivo is provided. Expand
Liposomal Irinotecan
TLDR
Low-performance liquid chromatographic analysis of plasma samples indicated that liposomal irinotecan was protected from inactivating hydrolysis to the carboxylate form, and this formulation exhibited substantially improved therapeutic effects. Expand
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.
TLDR
The strategy of coencapsulating both I&C in a single NP targeted to a specific cell type could potentially be used to treat different types of cancer. Expand
Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
TLDR
A polymer-lipid supported mesoporous silica nanoparticle (PLS-MSNs) is described here to facilitate intracellular delivery of anticancer drug and enhance the antitumor efficacy against MDR breast cancer cells. Expand
Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves.
TLDR
A novel MSNP delivery system capable of drug delivery based on the function of beta-cyclodextrin (beta-CD) nanovalves that are responsive to the endosomal acidification conditions in human differentiated myeloid and squamous carcinoma cell lines are reported. Expand
Development of High-Content Gemcitabine PEGylated Liposomes and Their Cytotoxicity on Drug-Resistant Pancreatic Tumour Cells
TLDR
Remote loading was not suitable for loading gemcitabine into liposomes, and minimal drug leakage, good stability, and significant improvement in cytotoxicity to the gem citabine-resistant pancreatic cancer cell lines were observed. Expand
Targeting Anticancer Drug Delivery to Pancreatic Cancer Cells Using a Fucose-Bound Nanoparticle Approach
TLDR
Intravenously injected L-fucose-bound liposomes carrying Cisplatin were successfully delivered to pancreatic cancer cells, mediating efficient tumor growth inhibition as well as prolonging survival in mouse xenograft models, indicating this modality represents a new strategy for pancreatic cancers cell-targeting therapy. Expand
Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals.
TLDR
The results indicate that MSNs are biocompatible, preferentially accumulate in tumors, and effectively deliver drugs to the tumors and suppress tumor growth. Expand
...
1
2
3
4
5
...